Biomarkers for Community-Acquired Pneumonia in the Emergency Department

Current Infectious Disease Reports

Volumn 16, Issue 12, 2014, Pages

  Florin, Todd A ^a,b   Ambroggio, Lilliam ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Adult; Biomarkers; Blood cultures; C reactive protein; Community acquired pneumonia; Diagnostic testing; Emergency medicine; Leukocyte count; Metabolomics; Pediatric; Polymerase chain reaction; Proadrenomedullin; Procalcitonin; Sputum cultures; Transcriptomics

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROADRENOMEDULLIN; PROCALCITONIN;

ADVERSE OUTCOME; BACTERIAL INFECTION; BACTERIUM CULTURE; BLOOD CULTURE; CHLAMYDOPHILA; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC TEST; EMERGENCY WARD; FALSE POSITIVE RESULT; GRAM STAINING; HUMAN; IMMUNE RESPONSE; LEUKOCYTE COUNT; MYCOPLASMA PNEUMONIAE; NUCLEIC ACID ANALYSIS; PLEURA FLUID; PNEUMOCOCCAL INFECTION; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW; SPUTUM CULTURE; URINE ANTIGEN TEST;

EID: 84920261130     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-014-0451-8     Document Type: Review

References (101)

1. Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med. 2007;161:1162–8.
2. Lode HM. Managing community-acquired pneumonia: a European perspective. Respir Med. 2007;101:1864–73.
3. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis Off Publ Inf Dis Soc Am. 2007;44 Suppl 2:S27–72. Evidence-based consensus guidelines for the management of community-acquired pneumonia in adults.
4. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Inf Dis Off Publ Inf Dis Soc Am. 2011;53:e25–76. Evidence-based consensus guidelines for the management of community-acquired pneumonia in children.
5. Florin TA, French B, Zorc JJ, Alpern ER, Shah SS. Variation in emergency department diagnostic testing and disposition outcomes in pneumonia. Pediatrics. 2013;132:237–44.
6. Neuman MI, Shah SS, Shapiro DJ, Hersh AL. Emergency department management of childhood pneumonia in the United States prior to publication of national guidelines. Acad Emerg Med Off J Soc Acad Emerg Med. 2013;20:240–6.
7. Neuman MI, Graham D, Bachur R. Variation in the use of chest radiography for pneumonia in pediatric emergency departments. Pediatr Emerg Care. 2011;27:606–10.
8. Dedier J, Singer DE, Chang Y, Moore M, Atlas SJ. Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med. 2001;161:2099–104.
9. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50.
10. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82.
11. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5:463–6.
12. Schutzle H, Forster J, Superti-Furga A, Berner R. Is serum procalcitonin a reliable diagnostic marker in children with acute respiratory tract infections? A retrospective analysis. Eur J Pediatr. 2009;168:1117–24.
13. Toikka P, Irjala K, Juven T, et al. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J. 2000;19:598–602.
14. Lynch T, Bialy L, Kellner JD, et al. A systematic review on the diagnosis of pediatric bacterial pneumonia: when gold is bronze. PLoS One. 2010;5:e11989.
15. Van den Bruel A, Thompson MJ, Haj-Hassan T, et al. Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review. BMJ. 2011;342:d3082.
16. Ballin A, Osadchy A, Klivitsky A, Dalal I, Lishner M. Age-related leukocyte and cytokine patterns in community-acquired bronchopneumonia. Isr Med Assoc J IMAJ. 2006;8:388–90.
17. Don M, Valent F, Korppi M, Canciani M. Differentiation of bacterial and viral community-acquired pneumonia in children. Pediatr Int Off J Jpn Pediatr Soc. 2009;51:91–6.
18. Elemraid MA, Rushton SP, Thomas MF, Spencer DA, Gennery AR, Clark JE. Utility of inflammatory markers in predicting the aetiology of pneumonia in children. Diagn Microbiol Infect Dis. 2014;79:458–62.
19. Hoshina T, Nanishi E, Kanno S, Nishio H, Kusuhara K, Hara T. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis. J Inf Chemother Off J Jpn Soc Chemother. 2014;20(10):616–20.
20. Moulin F, Raymond J, Lorrot M, et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child. 2001;84:332–6.
21. Summah H, Qu JM. Biomarkers: a definite plus in pneumonia. Mediat Inflamm. 2009;2009:675753.
22. Virkki R, Juven T, Rikalainen H, Svedstrom E, Mertsola J, Ruuskanen O. Differentiation of bacterial and viral pneumonia in children. Thorax. 2002;57:438–41.
23. Pereira JM, Teixeira-Pinto A, Basilio C, Sousa-Dias C, Mergulhao P, Paiva JA. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia? J Crit Care. 2013;28:970–4.
24. Korppi M, Heiskanen-Kosma T, Leinonen M. White blood cells, C-reactive protein and erythrocyte sedimentation rate in pneumococcal pneumonia in children. Eur Respir J. 1997;10:1125–9.
25. Purcell K, Fergie J. Lack of usefulness of an abnormal white blood cell count for predicting a concurrent serious bacterial infection in infants and young children hospitalized with respiratory syncytial virus lower respiratory tract infection. Pediatr Infect Dis J. 2007;26:311–5.
26. Luna CM. C-reactive protein in pneumonia: let me try again. Chest. 2004;125:1192–5.
27. Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011;139:1410–8.
28. Flood RG, Badik J, Aronoff SC. The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230 children. Pediatr Infect Dis J. 2008;27:95–9.
29. Heiskanen-Kosma T, Korppi M. Serum C-reactive protein cannot differentiate bacterial and viral aetiology of community-acquired pneumonia in children in primary healthcare settings. Scand J Infect Dis. 2000;32:399–402.
30. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection. 2000;28:68–73.
31. Smith RP, Lipworth BJ. C-reactive protein in simple community-acquired pneumonia. Chest. 1995;107:1028–31.
32. Zhydkov A, Christ-Crain M, Thomann R, et al. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia. Clin Chem Lab Med CCLM / FESCC 2014. doi:10.1515/cclm-2014-0456.
33. Hohenthal U, Hurme S, Helenius H, et al. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. Clin Microbiol Infect. 2009;15:1026–32.
34. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med. 2008;121:219–25.
35. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J. 2008;32:726–32.
36. Coelho L, Povoa P, Almeida E, et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care. 2007;11:R92.
37. Hirakata Y, Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;61:170–4.
38. Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF, Shah PM. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect. 2002;8:93–100.
39. Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett. 1984;167:93–7.
40. Becker KL, Nylen ES, White JC, Muller B, Snider Jr RH. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004;89:1512–25.
41. Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000;28:977–83.
42. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care. 2010;14:203.
43. Snider Jr RH, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med Off Publ Am Fed Clin Res. 1997;45:552–60.
44. Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10.
45. Soni NJ, Samson DJ, Galaydick JL, Vats V, Pitrak DL, Aronson N. Procalcitonin-guided antibiotic therapy. Comparative effectiveness review no. 78. (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007-10058-I.) AHRQ Publication No. 12(13)-EHC124-EF. Rockville: Agency for Healthcare Research and Quality; 2012. A systematic review of 18 randomized trials demonstrating decreased antibiotic use in adult patients with community-acquired pneumonia when procalcitonin guidance is used.
46. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–7.
47. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84–93.
48. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302:1059–66.
49. Andrijevic I, Matijasevic J, Andrijevic L, Kovacevic T, Zaric B. Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia. Ann Thorac Med. 2014;9:162–7.
50. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med. 2006;34:2596–602.
51. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164:396–402.
52. Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J. 2000;19:679–87.
53. Gomez B, Bressan S, Mintegi S, et al. Diagnostic value of procalcitonin in well-appearing young febrile infants. Pediatrics. 2012;130:815–22. This retrospective study of 1112 well-appearing febrile infants <3 months of age with fever without source demonstrated that procalcitonin performs better than C-reactive protein in identifying infants with invasive bacterial infections and was the best marker to rule out invasive bacterial infection.
54. Yo CH, Hsieh PS, Lee SH, et al. Comparison of the test characteristics of procalcitonin to C-reactive protein and leukocytosis for the detection of serious bacterial infections in children presenting with fever without source: a systematic review and meta-analysis. Ann Emerg Med. 2012;60:591–600.
55. Andreola B, Bressan S, Callegaro S, Liverani A, Plebani M, Da Dalt L. Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. Pediatr Infect Dis J. 2007;26:672–7.
56. Leroy S, Fernandez-Lopez A, Nikfar R, et al. Association of procalcitonin with acute pyelonephritis and renal scars in pediatric UTI. Pediatrics. 2013;131:870–9.
57. Unal S, Arslankoylu AE, Kuyucu N, Aslan G, Erdogan S. Procalcitonin is more useful than C-reactive protein in differentiation of fever in patients with sickle cell disease. J Pediatr Hematol Oncol. 2012;34:85–9.
58. Kasem AJ, Bulloch B, Henry M, Shah K, Dalton H. Procalcitonin as a marker of bacteremia in children with fever and a central venous catheter presenting to the emergency department. Pediatr Emerg Care. 2012;28:1017–21.
59. Prat C, Dominguez J, Rodrigo C, et al. Procalcitonin, C-reactive protein and leukocyte count in children with lower respiratory tract infection. Pediatr Infect Dis J. 2003;22:963–8.
60. Hatzistilianou M, Hitoglou S, Gougoustamou D, et al. Serum procalcitonin, adenosine deaminase and its isoenzymes in the aetiological diagnosis of pneumonia in children. Int J Immunopathol Pharmacol. 2002;15:119–27.
61. Korppi M, Remes S, Heiskanen-Kosma T. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol. 2003;35:56–61.
62. Korppi M, Remes S. Serum procalcitonin in pneumococcal pneumonia in children. Eur Respir J. 2001;17:623–7.
63. Don M, Korppi M, Valent F, Vainionpaa R, Canciani M. Human metapneumovirus pneumonia in children: results of an Italian study and mini-review. Scand J Infect Dis. 2008;40:821–6.
64. Galetto-Lacour A, Alcoba G, Posfay-Barbe KM, et al. Elevated inflammatory markers combined with positive pneumococcal urinary antigen are a good predictor of pneumococcal community-acquired pneumonia in children. Pediatr Infect Dis J. 2013;32:1175–9. This prospective study of pneumonia biomarkers in 75 children included one of the most comprehensive sets of etiology markers, including antibodies against 5 pneumococcal surface proteins, viral serologies, nasopharyngeal cultures and polymerase chain reaction for 13 respiratory viruses, blood pneumococcal PCR, pneumococcal urinary antigen, procalcitonin and C-reactive protein. The study found that PCT and CRP are reliable predictors of pneumococcal pneumonia, and the combination of elevated PCT or CRP with a positive urinary antigen test is a strong predictor of pneumococcal pneumonia.
65. Nascimento-Carvalho CM, Cardoso MR, Barral A, et al. Seasonal patterns of viral and bacterial infections among children hospitalized with community-acquired pneumonia in a tropical region. Scand J Infect Dis. 2010;42:839–44.
66. Esposito S, Tagliabue C, Picciolli I, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respir Med. 2011;105:1939–45.
67. Baer G, Baumann P, Buettcher M, et al. Procalcitonin Guidance to Reduce Antibiotic Treatment of Lower Respiratory Tract Infection in Children and Adolescents (ProPAED): a randomized controlled trial. PLoS One. 2013;8:e68419. The randomized study examined use of procalcitonin guidance in children and found that procalcitonin guidance reduced antibiotic exposure with no difference in impairment of daily activities.
68. Hirata Y, Mitaka C, Sato K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab. 1996;81:1449–53.
69. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides. 2001;22:1693–711.
70. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25:1369–72.
71. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care. 2006;10:R96.
72. Albrich WC, Dusemund F, Ruegger K, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Inf Dis. 2011;11:112. This study derived a new clinical algorithm that combines the CURB-65 score, an established clinical severity score for adults with CAP, with proadrenomedullin to produce the CURB65-A score. This new score provided better prediction of death and adverse events than the CURB65 score.
73. Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest. 2009;136:823–31.
74. Bello S, Lasierra AB, Minchole E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J. 2012;39:1144–55.
75. Renaud B, Schuetz P, Claessens YE, Labarere J, Albrich W, Mueller B. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia. Chest. 2012;142:1447–54.
76. Sarda Sanchez M, Hernandez JC, Hernandez-Bou S, Teruel GC, Rodriguez JV, Cubells CL. Pro-adrenomedullin usefulness in the management of children with community-acquired pneumonia, a preliminar prospective observational study. BMC Res Notes. 2012;5:363.
77. Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2004;39:165–9.
78. Murdoch DR, O’Brien KL, Driscoll AJ, et al. Laboratory methods for determining pneumonia etiology in children. Clin Infect Dis. 2012;54 Suppl 2:S146–52.
79. Laing R, Slater W, Coles C, et al. Community-acquired pneumonia in Christchurch and Waikato 1999–2000: microbiology and epidemiology. N Z Med J. 2001;114:488–92.
80. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis. 2008;47:989–96.
81. Abdullahi O, Nyiro J, Lewa P, Slack M, Scott JA. The descriptive epidemiology of Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage in children and adults in Kilifi district, Kenya. Pediatr Infect Dis J. 2008;27:59–64.
82. Myers AL, Hall M, Williams DJ, et al. Prevalence of bacteremia in hospitalized pediatric patients with community-acquired pneumonia. Pediatr Infect Dis J. 2013;32:736–40. This multicenter retrospective study of 658 children with CAP found a bacteremia prevalence rate of 7%, with blood culture results changing antibiotic management in 26-65% of patients. The study concluded that blood cultures are useful in hospitalized children with CAP and should prompt a change to narrow-spectrum antibiotic therapy if positive with sensitive organisms.
83. Carvalho Mda G, Tondella ML, McCaustland K, et al. Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol. 2007;45:2460–6.
84. Song JY, Eun BW, Nahm MH. Diagnosis of pneumococcal pneumonia: current pitfalls and the way forward. Infect Chemother. 2013;45:351–66.
85. Butler JC, Bosshardt SC, Phelan M, et al. Classical and latent class analysis evaluation of sputum polymerase chain reaction and urine antigen testing for diagnosis of pneumococcal pneumonia in adults. J Inf Dis. 2003;187:1416–23.
86. Michelow IC, Lozano J, Olsen K, et al. Diagnosis of Streptococcus pneumoniae lower respiratory infection in hospitalized children by culture, polymerase chain reaction, serological testing, and urinary antigen detection. Clin Inf Dis Off Publ Inf Dis Soc Am. 2002;34:E1–11.
87. Stralin K, Tornqvist E, Kaltoft MS, Olcen P, Holmberg H. Etiologic diagnosis of adult bacterial pneumonia by culture and PCR applied to respiratory tract samples. J Clin Microbiol. 2006;44:643–5.
88. Abdeldaim G, Herrmann B, Molling P, et al. Usefulness of real-time PCR for lytA, ply, and Spn9802 on plasma samples for the diagnosis of pneumococcal pneumonia. Clin Microbiol Inf Off Publ Eur Soc Clin Microbiol Inf Dis. 2010;16:1135–41.
89. Azzari C, Cortimiglia M, Moriondo M, et al. Pneumococcal DNA is not detectable in the blood of healthy carrier children by real-time PCR targeting the lytA gene. J Med Microbiol. 2011;60:710–4.
90. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113:701–7.
91. Rello J, Lisboa T, Lujan M, et al. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest. 2009;136:832–40.
92. Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis. 2011;52 Suppl 4:S296–304.
93. Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol. 2003;41:2810–3.
94. Tzeng DH, Lee YL, Lin YH, Tsai CA, Shi ZY. Diagnostic value of the Binax NOW assay for identifying a pneumococcal etiology in patients with respiratory tract infection. J Microbiol Immunol Infect. 2006;39(1):39–44.
95. Murdoch DR. Diagnosis of Legionella infection. Clin Infect Dis. 2003;36:64–9.
96. Neuman MI, Harper MB. Evaluation of a rapid urine antigen assay for the detection of invasive pneumococcal disease in children. Pediatrics. 2003;112:1279–82.
97. Stralin K, Holmberg H. Usefulness of the Streptococcus pneumoniae urinary antigen test in the treatment of community-acquired pneumonia. Clin Infect Dis. 2005;41:1209–10.
98. Ramilo O, Allman W, Chung W, et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood. 2007;109:2066–77. This study used RNA microarray technology on peripheral blood leukocytes to discover gene expression patterns able to discriminate patients with influenza A infection from those with S. pneumoniae infection, suggesting a paradigm shift in etiologic diagnosis in pneumonia.
99. Mejias A, Dimo B, Suarez NM, et al. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med. 2013;10:e1001549.
100. Slupsky CM, Rankin KN, Fu H, et al. Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profile. J Proteome Res. 2009;8:5550–8. This study found that the urinary metabolite profile for pneumococcal pneumonia was significantly different from profiles for viral and other bacterial forms of pneumonia. This suggests that an easily obtainable, noninvasive specimen such as urine may be used to predict etiology and guide antibiotic therapy in CAP.
101. Laiakis EC, Morris GA, Fornace AJ, Howie SR. Metabolomic analysis in severe childhood pneumonia in the Gambia, West Africa: findings from a pilot study. PLoS One 2010;5.